Foundation Medicine announced new data demonstrating that FoundationOne identified actionable genomic alterations in a broad range of pediatric cancers. These data will be presented today in a poster highlights presentation at the 2014 American Society of Clinical Oncology Annual Meeting, abstract number 10035. Fully informative genomic profiling was conducted using FoundationOne on 400 pediatric tumors from patients 21 years old or younger at the time of sample procurement. Genomic alterations were identified in a majority of 326 unselected pediatric cancer clinical cases, and 241 of these patients were found to have at least one alteration targeted by an approved therapy or investigational therapy in clinical trials. These results suggest that routine use of accurate, comprehensive genomic profiling with FoundationOne or FoundationOne Heme in pediatric patients may inform treatment options.